The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, proudly announces ...

The first line of pharmacological treatment for schizophrenia is antipsychotic medication. However, antipsychotic medications are ineffective in more than 30% of people with the disorder. This is ...

The global acute respiratory distress syndrome (ARDS) treatment market was valued at approximately USD $$ billion in 2022 and is expected to grow at a robust CAGR of more than $% during the forecast ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

Please provide your email address to receive an email when new articles are posted on . Invited patients had 32% of days covered for maintenance inhalers, whereas control patients had a smaller ...

In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

On a more positive note, new research also recently found a link between chronic obstructive pulmonary disease (COPD) symptoms and GLP-1 medications. The study found people with type 2 diabetes ...

This finding highlights the potential benefits of these medications beyond glucose control, particularly for patients managing both T2D and COPD. Recent studies have suggested that SGLT-2is, GLP-1RAs, ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...